Cancer Research
GeoVax Study Shows Gedeptin May Enhance Checkpoint Inhibitor Responses in Resistant Tumors
Peer-reviewed research in JCI Insight demonstrates GeoVax's Gedeptin platform can sensitize resistant tumors to immune checkpoint inhibitors and activate systemic anti-tumor immunity, potentially broadening cancer immunotherapy efficacy.
Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment Outcomes
Oncotelic Therapeutics is leveraging its Deciparticle platform and Sapu003 program to enhance drug delivery for existing cancer therapies, addressing key challenges in oncology treatment.
Microglia Protein Production Linked to Pediatric Brain Tumor Spread, Study Finds
Scientists discovered that microglia in the brain produce fibronectin proteins, enabling diffuse midline gliomas to spread, highlighting a potential therapeutic target for companies like CNS Pharmaceuticals.
Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for Lead Cancer Drug Candidate
Onco-Innovations Limited successfully produced nearly a kilogram of the B4 precursor for its ONC010 PNKP inhibitor, advancing toward clinical trials and scalable production.
Sexual Difficulties Common in Young Cancer Survivors, Study Finds
A new doctoral study from Karolinska Institutet reveals that young adults often experience sexual problems after cancer treatment, with severity varying by cancer type and treatment intensity.
Brain Cell Division Errors May Unlock New Cancer Treatments, Study Finds
Researchers at the University of Virginia have discovered that errors in brain cell division during development could trigger cancer and developmental disorders, offering new pathways for treatment and prevention.
Scientists Make Progress on Blood Test for Early Lung Cancer Detection
Researchers are developing a blood test that could identify individuals at high risk for lung cancer, addressing the limitations of current screening focused solely on smoking history.
UNC Researchers Develop More Targeted Immunotherapy for Acute Myeloid Leukemia
Scientists at the University of North Carolina have engineered immune cells that selectively destroy acute myeloid leukemia while sparing healthy blood tissue, potentially expanding treatment options for patients.
Kairos Pharma Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Kairos Pharma has been recognized with the 2026 GHP Magazine Healthcare & Pharmaceutical Award as the USA leader in drug resistance development, highlighting its work on cancer therapeutics that address treatment resistance.
GeoVax Highlights Gedeptin's Role in Overcoming Immune Resistance in Cold Tumors
GeoVax Labs emphasizes its Gedeptin platform's potential to enhance checkpoint inhibitor efficacy by modulating the tumor microenvironment, positioning it as a key combination immunotherapy for immunologically cold tumors.
Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress
Kairos Pharma CEO Dr. John Yu will present at the LD Micro Invitational, providing updates on the company's clinical trials for ENV-105, a promising oncology candidate targeting drug resistance in cancer.
Qdrant Powers AI Platform Indexing 28 Million PubMed Abstracts to Accelerate Cancer Research
Qdrant's vector search technology enables Sapu's AI platform to index and query all 28 million PubMed abstracts, accelerating biomedical discovery and cancer research.
Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
New Study Links Breast Tissue Aging to Increased Breast Cancer Risk in Older Women
Research mapping breast tissue changes with age explains higher breast cancer rates in older women and may guide new treatments.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
LIXTE Biotechnology Advances Precision Cancer Treatment with Novel PP2A Inhibitor
LIXTE Biotechnology is pioneering a new approach in oncology with its lead compound LB-100, which enhances chemotherapy and radiation efficacy while reducing side effects, potentially improving patient outcomes.
Alliance Pavers Partners with M/I Homes for 2026 Pelotonia Cancer Research Home Build in Orlando
Alliance Pavers joins M/I Homes to construct a designated Pelotonia Home in Orlando, directing funds toward cancer research and local charities while matching donations to amplify community impact.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
University of Calgary Seeks 10,000 Toenail Samples for Radon Exposure and Lung Cancer Study
Canadian researchers are collecting toenail samples to develop better methods for measuring radon exposure and its connection to lung cancer risk, potentially enabling earlier diagnosis and treatment.
New Research Identifies Key Mechanism Behind Cancer Immunotherapy Failures
Ohio State University researchers have discovered a previously unknown stress pathway that explains why immunotherapy fails in most cancer patients, potentially paving the way for more effective treatments.
Lund University Researchers Identify Mechanism Allowing Leukemia Cells to Evade Immune System
Researchers at Lund University have discovered why acute myeloid leukemia cells resist immunotherapy, potentially paving the way for more effective treatments for this aggressive blood cancer.